Skip to main content

Advertisement

SpringerLink
Log in

Nanomedicines for the Treatment of CNS Diseases

  • GUEST COMMENTARY
  • Published:
Journal of Neuroimmune Pharmacology Aims and scope Submit manuscript

Abstract

Targeting and delivering macromolecular therapeutics to the central nervous system (CNS) has been a major challenge. The blood–brain barrier (BBB) is the main obstacle that must be overcome to allow compounds to reach their targets in the brain. Therefore, much effort has been channelled into improving transport of therapeutics across the BBB and into the CNS including the use of nanoparticles. In this thematic issue, several reviews and original research are presented that address “Nanomedicines for CNS Diseases.” The articles in this issue are concentrated on either CNS-HIV disease or CNS tumors. In regards to CNS-HIV disease, there are two reviews that discuss the role of nanoparticles for improving the delivery of HIV therapeutics to the CNS. In addition, there are two original articles focusing on therapies for CNS-HIV, one of them uses nanoparticles for delivery of siRNA specific to a key protein in autophagy to microglia, and another discusses nanoparticle delivery of a soluble mediator to suppress neuroinflammation. Furthermore, a comprehensive review about gene therapy for CNS neurological diseases is also included. Finally, this issue also includes review articles on enhanced drug targeting to CNS tumors. These articles include a review on the use of nanoparticles for CNS tumors, a review on functionalization (ligands) of nanoparticles for drug targeting to the brain tumor by overcoming BBB, and the final review discusses the use of macrophages as a delivery vehicle to CNS tumors. This thematic issue provides a wealth of knowledge on using nanomedicines for CNS diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aalinkeel R et al. (2016) Galectin-1 reduces neuroinflammation via modulation of Nitric Oxide-Arginase signaling in HIV-1 transfected microglia: A Gold nanoparticle-Galectin-1 “nanoplex” a possible neurotherapeutic. J Neuroimmune Pharmacol

  • Abbott NJ (2004) Prediction of blood–brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. Drug Discov Today Technol 1:407–415

    Article  CAS  PubMed  Google Scholar 

  • Abbott NJ (2005) Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol Neurobiol 25:5–23

    Article  PubMed  Google Scholar 

  • Alyautdin R, Khalin I, Nafeeza MI, Haron MH, Kuznetsov D (2014) Nanoscale drug delivery systems and the blood-brain barrier. Int J Nanomedicine 9:795–811. doi:10.2147/IJN.S52236

    CAS  PubMed  PubMed Central  Google Scholar 

  • Association ABT (2016a) Brain tumor statistics. http://www.abta.org/about-us/news/brain-tumor-statistics/

  • Association ABT (2016b) Glioblastoma (GBM). http://www.abta.org/brain-tumor-information/types-of-tumors/glioblastoma.html

  • Ciccarelli N et al (2013) Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia. Antivir Ther 18:153–160

    Article  PubMed  Google Scholar 

  • Cusini A et al (2013) Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr 63:170–171

    Article  Google Scholar 

  • Cysique L, Brew BJ (2011) Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol 17:176–183

    Article  PubMed  Google Scholar 

  • DeMarino C, Schwab A, Pleet M, Mathiesen A, Friedman J, El-Hage N, Kashanchi F (2016) Biodegradable nanoparticles for delivery of therapeutics in CNS infection. J Neuroimmune Pharmacol

  • Edén A et al (2010) HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 202:1819–1825

    Article  PubMed  PubMed Central  Google Scholar 

  • Edlin B, Weinstein R, Whaling S, Ou C, Connolly P, Moore J, Bitran J (1992) Zidovudine-interferon-alpha combination therapy in patients with advanced human immunodeficiency virus type 1 infection: biphasic response of p24 antigen and quantitative polymerase chain reaction. J Infect Dis 165:793–798

    Article  CAS  PubMed  Google Scholar 

  • Fiandra L, Capetti A, Sorrentino L, Corsi F (2016) Nanoformulated antiretrovirals for penetration of the central nervous system: state of the art J Neuroimmune Pharmacol

  • Gao H (2016) Perspectives on dual targeting delivery systems for brain tumors. J Neuroimmune Pharmacol

  • Gomes MJ, Fernandes C, S. Martins, Borges F, Sarmento B (2016) Tailoring lipid and polymeric nanoparticles as siRNA carriers towards the blood-brain barrier - from targeting to safe administration. J Neuroimmune Pharmacol

  • Hellmuth J, Valcour V, Spudich S (2015) CNS reservoirs for HIV: implications for eradication. Journal of Virus Eradication 1:67–71

    PubMed  PubMed Central  Google Scholar 

  • Hirschberg H, Madsen SJ (2016) ell Mediated photothermal therapy of brain tumors. J Neuroimmune Pharmacol

  • Joshi CR, Labhasetwar V, Ghorpade A (2016) Destination brain: the past, present, and future of therapeutic gene delivery. J Neuroimmune Pharmacol

  • Mahajan S et al. (2010) Enhancing the delivery of anti retroviral drug “Saquinavir” across the blood brain barrier using nanoparticles

  • Mahajan S et al (2012) Suppression of MMP-9 expression in brain microvascular endothelial cells (BMVEC) using a gold nanorod (GNR)-siRNA nanoplex. Immunol Investig 41:337–355

    Article  CAS  Google Scholar 

  • Meng J, Agrahari V, Youm I (2016) Advances in targeted drug delivery approaches for the central nervous system tumors: the inspiration of nanobiotechnology. J Neuroimmune Pharmacol

  • Michaud D, Schiff D, Batchelor T (2016) Incidence of primary brain tumors. UpToDate, Waltham, MA

  • NIH announces plan to increase funding toward a cure for HIV/AIDS (2013) https://www.nih.gov/news-events/news-releases/nih-announces-plan-increase-funding-toward-cure-hiv/aids

  • Rodriguez M, Kaushik A, Lapierre J, Dever S, El-Hage N, Nair M (2016) Electro-magnetic nano-particle bound beclin1 siRNA crosses the blood-brain barrier to attenuate the inflammatory effects of HIV-1 infection in vitro. J Neuroimmune Pharmacol

  • Serlin Y, Shelef I, Knyazer B (2015) Friedman A. Anatomy and physiology of the blood-brain barrier Semin Cell Dev Biol 38:2–6. doi:10.1016/j.semcdb.2015.01.002

    Article  PubMed  Google Scholar 

  • Serramía M et al (2015) In vivo delivery of siRNA to the brain by carbosilane dendrimer. J Control Release 200:60–70

    Article  PubMed  Google Scholar 

  • Shiramizu B et al (2012) Failure to clear intra-monocyte HIV infection linked to persistent neuropsychological testing impairment after first-line combined antiretroviral therapy. Journal of neurovirology 18:69–73

    Article  CAS  PubMed  Google Scholar 

  • Valcour V, Sithinamsuwan P, Letendre S, Ances B (2011) Pathogenesis of HIV in the central nervous system. Current HIV/AIDS reports 8:54–61

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

New York State Department of Health, Empire Clinical Research Investigator Program (ECRIP) Awards (Reynolds). Authors would also like to acknowledge Dr. Howard Gendelman for his ongoing help and dedication to nanomedicine projects.

Author information

Authors and Affiliations

  1. Department of Medicine, University at Buffalo, The State University of New York, Clinical and Translational Research Center, Room 6075, 875 Ellicott Street, Buffalo, NY, 14203, USA

    Jessica L. Reynolds

  2. Department of Pharmaceutical Sciences, University of Nebraska Medical Center, 986025 Nebraska Medical Center, Omaha, NE, 68198-6025, USA

    Ram I. Mahato

Authors
  1. Jessica L. Reynolds
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ram I. Mahato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jessica L. Reynolds.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reynolds, J.L., Mahato, R.I. Nanomedicines for the Treatment of CNS Diseases. J Neuroimmune Pharmacol 12, 1–5 (2017). https://doi.org/10.1007/s11481-017-9725-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11481-017-9725-x

Keywords

Search

Navigation